In a webinar organized by the Hong Kong Association for the Study of Liver Diseases (HKASLD), Professor Kim, Seung-Up and Dr. Wong, Yu-Jun Eugene introduced the new paradigms in viral hepatitis disease control. While Prof. Kim discussed some topics of hepatitis B virus (HBV) management, including the increased risk of kidney disease with long-term antiviral use and the appropriate first-line agents to mitigate this risk, Dr. Wong presented the challenges of hepatitis C virus (HCV) management and access to care, highlighting the efficacy and safety of the direct-acting antiviral (DAA) treatment of sofosbuvir/ velpatasvir (SOF/VEL) in HCV patients and the simplified treatment monitoring in reducing the healthcare burden.

Glossary: AFP: Alpha-fetoprotein; aHR: Adjusted hazard ratio; ALT: Alanine aminotransferase; cccDNA: Close covalent circular deoxyribonucleic acid; CHB: Chronic hepatitis B; cHR: Crude hazard ratio; CI: Confidence interval; FIB-4: Fibrosis-4 index; HBsAg: Hepatitis B surface antigen; HBV: Hepatiti

Glossary: DAA: Direct-acting antiviral; GT3: Genotype 3; HCV: Hepatitis C virus; IV: Intravenous; LFU: Lost to follow-up; NS5A: Nonstructural protein 5A; RBV: Ribavirin; RNA: Ribonucleic acid; SOF/VEL: Sofobuvir/velpatasvir; SVR: Sustained virologic response

Glossary: DAA: Direct-acting antiviral; HCV: Hepatitis C virus; RNA: Ribonucleic acid; SoC: Standard of care; SOL/VEL: Sofosbuvir/velpatasvir; SVR: Sustained virologic response; the US: The United States

Glossary: aRR: Adjusted rate ratio; CI: Confidence interval; HCC: Hematocellular carcinoma; HCV: Hepatitis C virus

Glossary: BC: Breast cancer; HCV: Hepatitis C virus; IDU: Injection drug user; LFU: Lost to follow-up; OR: Odds ratio; RNA: Ribonucleic acid; SVR: Sustained virologic response